Overexpression of the urokinase receptor splice variant uPAR-del4/5 in breast cancer cells affects cell adhesion and invasion in a dose-dependent manner and modulates transcription of tumor-associated genes

Biological Chemistry

Volumn 393, Issue 12, 2012, Pages 1449-1455

  Grismayer, Bettina ^c   Sato, Sumito ^a   Kopitz, Charlotte ^a   Ries, Christian ^b   Soelch, Susanne ^a   Schmitt, Manfred ^a   Baretton, Gustavo ^c   Kruger, Achim ^a   Luther, Thomas ^c,d   Kotzsch, Matthias ^c   Magdolen, Viktor ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^d Medizinisches Labor Ostsachsen   (Germany)

Author keywords

Adhesion; Breast cancer; Differential gene expression; Invasion; MMP 9; UPAR splice variant

Indexed keywords

ALPHA4 INTEGRIN; COLLAGEN TYPE 4; COLLAGENASE 3; CYCLIN D2; GELATINASE B; GRANULOCYTE COLONY STIMULATING FACTOR; HEPSIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6 RECEPTOR; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; SELECTIN; STROMELYSIN; UROKINASE RECEPTOR; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN RECEPTOR; VITRONECTIN;

BREAST CANCER; CANCER CELL; CELL ADHESION; CELL GROWTH; CELL INVASION; CELL PROLIFERATION; CONFERENCE PAPER; CONTROLLED STUDY; DOSE RESPONSE; EXTRACELLULAR MATRIX; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GENE; UPREGULATION;

BREAST; BREAST NEOPLASMS; CELL ADHESION; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MATRIX METALLOPROTEINASE 9; NEOPLASM INVASIVENESS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; RNA SPLICING; UP-REGULATION;

EID: 84869459789     PISSN: 14316730     EISSN: 14374315     Source Type: Journal    
DOI: 10.1515/hsz-2012-0206     Document Type: Conference Paper

References (28)

1. Blasi, F. and Sidenius, N. (2010). The urokinase receptor: focused cell surface proteolysis, cell adhesion and signaling. FEBS Lett. 584, 1923-1930.
2. Bauvois, B. (2011). New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: outside-in signaling and relationship to tumor progression. Biochim. Biophys. Acta 1825, 29-36.
3. Coussens, L.M., Fingleton, B., and Matrisian, L.M. (2002). Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295, 2387-2392.
4. Hauser, S., Bickel, L., Weinspach, D., Gerg, M., Sch ä fer, M.K., Pfeifer, M., Hazin, J., Schelter, F., Weidle, U.H., Ramser, J., et al. (2011). Full-length L1CAM and not its Δ2Δ 27 splice variant promotes metastasis through induction of gelatinase expression. PLoS One 6, e18989.
5. Heinonen, M., Hemmes, A., Salmenkivi, K., Abdelmohsen, K., Vilen, S.T., Laakso, M., Leidenius, M., Salo, T., Hautaniemi, S., Gorospe, M., et al. (2011). Role of RNA binding protein HuR in ductal carcinoma in situ of the breast. J. Pathol. 224, 529-539.
6. Høyer-Hansen, G. and Lund, I.K. (2007). Urokinase receptor variants in tissue and body fluids. Adv. Clin. Chem. 44, 65-102.
7. Kessenbrock, K., Plaks, V., and Werb, Z. (2010). Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141, 52-67.
8. Klein, T. and Bischoff, R. (2011). Physiology and pathophysiology of matrix metalloproteases. Amino Acids 41, 271-290.
9. Kotzsch, M., Farthmann, J., Meye, A., Fuessel, S., Baretton, G., Tjan-Heijnen, V.C., Schmitt, M., Luther, T., Sweep, F.C., Magdolen, V., et al. (2005). Prognostic relevance of uPAR-del4/5 and TIMP-3 mRNA expression levels in breast cancer. Eur. J. Cancer 41, 2760-2768.
10. Kotzsch, M., Sieuwerts, A.M., Grosser, M., Meye, A., Fuessel, S., Meijer-van Gelder, M.E., Smid, M., Schmitt, M., Baretton, G., Luther, T., et al. (2008). Urokinase receptor splice variant uPAR-del4/5-associated gene expression in breast cancer: identification of rab31 as an independent prognostic factor. Breast Cancer Res. Treat. 111, 229-240.
11. Kotzsch, M., Dorn, J., Doetzer, K., Schmalfeldt, B., Krol, J., Baretton, G., Kiechle, M., Schmitt, M., and Magdolen, V. (2011). mRNA expression levels of the biological factors uPAR, uPAR-del4/5 and rab31, displaying prognostic value in breast cancer, are not clinically relevant in advanced ovarian cancer. Biol. Chem. 392, 1047-1051.
12. Kriegbaum, M.C., Persson, M., Haldager, L., Alpizar-Alpizar, W., Jacobsen, B., Gardsvoll, H., Kjaer, A., and Ploug, M. (2011). Rational targeting of the urokinase receptor (uPAR): development of antagonists and non-invasive imaging probes. Curr. Drug Targets 12, 1711-1728.
13. Kunigal, S., Lakka, S.S., Gondi, C.S., Estes, N., and Rao, J.S. (2007). RNAi-mediated downregulation of urokinase plasminogen activator receptor and matrix metalloprotease-9 in human breast cancer cells results in decreased tumor invasion, angiogenesis and growth. Int. J. Cancer 121, 2307-2316.
14. Luther, T., Magdolen, V., Albrecht, S., Kasper, M., Riemer, C., Kessler, H., Graeff, H., Muller, M., and Schmitt, M. (1997). Epitope-mapped monoclonal antibodies as tools for functional and morphological analyses of the human urokinase receptor in tumor tissue. Am. J. Pathol. 150, 1231-1244.
15. Luther, T., Kotzsch, M., Meye, A., Langerholc, T., Fussel, S., Olbricht, N., Albrecht, S., Ockert, D., Muehlenweg, B., Friedrich, K., et al. (2003). Identification of a novel urokinase receptor splice variant and its prognostic relevance in breast cancer. Thromb. Haemost. 89, 705-717.
16. Mengele, K., Napieralski, R., Magdolen, V., Reuning, U., Gkazepis, A., Sweep, F., Brunner, N., Foekens, J., Harbeck, N., and Schmitt, M. (2010). Characteristics of the level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1. Expert Rev. Mol. Diagn. 10, 947-962.
17. Montuori, N., Visconte, V., Rossi, G., and Ragno, P. (2005). Soluble and cleaved forms of the urokinase-receptor: degradation products or active molecules? Thromb. Haemost. 93, 192-198.
18. Overall, C.M. and López-Otín, C. (2002). Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat. Rev. Cancer 2, 657-672.
19. Rao, N.K., Shi, G.P., and Chapman, H.A. (1995). Urokinase receptor is a multifunctional protein: influence of receptor occupancy on macrophage gene expression. J. Clin. Invest. 96, 465-474.
20. Ries, C., Pitsch, T., Mentele, R., Zahler, S., Egea, V., Nagase, H., and Jochum, M. (2007). Identification of a novel 82 kDa proMMP-9 species associated with the surface of leukaemic cells: (auto-) catalytic activation and resistance to inhibition by TIMP-1. Biochem. J. 405, 547-558.
21. Sato, S., Kopitz, C., Grismayer, B., Beaufort, N., Reuning, U., Schmitt, M., Luther, T., Kotzsch, M., Kruger, A., and Magdolen, V. (2010). Overexpression of the urokinase receptor mRNA splice variant uPAR-del4/5 affects tumor-associated processes of breast cancer cells in vitro and in vivo. Breast Cancer Res. Treat. 127, 649-657.
22. Schmalfeldt, B., Prechtel, D., Härting, K., Späthe, K., Rutke, S., Konik, E., Fridman, R., Berger, U., Schmitt, M., Kuhn, W., et al. (2001). Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin. Cancer Res. 7, 2396-2404.
23. Schmitt, M., Mengele, K., Napieralski, R., Magdolen, V., Reuning, U., Gkazepis, A., Sweep, F., Brunner, N., Foekens, J., and Harbeck, N. (2010). Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1. Expert Rev. Mol. Diagn. 10, 1051-1067.
24. Smith, H.W. and Marshall, C.J. (2010). Regulation of cell signalling by uPAR. Nat. Rev. Mol. Cell Biol. 11, 23-36.
25. Subramanian, R., Gondi, C.S., Lakka, S.S., Jutla, A., and Rao, J.S. (2006). siRNA-mediated simultaneous downregulation of uPA and its receptor inhibits angiogenesis and invasiveness triggering apoptosis in breast cancer cells. Int. J. Oncol. 28, 831-839.
26. Tang, C.H. and Wei, Y. (2008). The urokinase receptor and integrins in cancer progression. Cell Mol. Life Sci. 65, 1916-1932.
27. Tran, H., Maurer, F., and Nagamine, Y. (2003). Stabilization of urokinase and urokinase receptor mRNAs by HuR is linked to its cytoplasmic accumulation induced by activated mitogenactivated protein kinase-activated protein kinase 2. Mol. Cell Biol. 23, 7177-7188.
28. Xu, X., Gårdsvoll, H., Yuan, C., Lin, L., Ploug, M., and Huang, M. (2012). Crystal structure of the urokinase receptor in a ligand-free form. J. Mol. Biol. 416, 629-641.